(Press-News.org) WASHINGTON, DC -- Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation – based on age, diagnosis, and family history of breast or ovarian cancer – reported that their doctors urged them to be tested for the genes, according to a research team from the Perelman School of Medicine at the University of Pennsylvania.
The findings, which will be presented during the American Association for Cancer Research Annual Meeting 2013 (Presentation #1358), were drawn from surveys completed by 2,258 women between 18 and 64 who were diagnosed with breast cancer in Pennsylvanian in 2007. While physician recommendations for genetic testing appeared to be targeted at the proper group of patients – just 9 percent of women at low risk of having one of the mutated genes were advised to undergo testing – the finding that such a large portion of high-risk women did not receive a testing recommendation underscores the need to improve provider education about the utility and availability of testing. Among women at high risk of mutation, the analysis found that those who were older, had lower income, and were employed were less likely to have received a recommendation for testing.
###
The study will be presented by Anne Marie McCarthy, PhD, in the Behavioral and Social Science in Cancer Prevention Poster Research Poster Session, Hall A-C, Poster Section 11, at the Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, DC 20001, from 1 p.m. to 5 p.m. ET on Monday, April 8, 2013.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.
Nearly half of breast cancer patients at risk of having BRCA mutations not sent for genetic testing
2013-04-09
ELSE PRESS RELEASES FROM THIS DATE:
Adding cetuximab to chemotherapy enables select patients with advanced colorectal cancer and liver metastasis to undergo surgery, extending survival by several months
2013-04-09
In this News Digest:
Summary of a study being published online April 8, 2013 in the Journal of Clinical Oncology, reports that adding cetuximab (Erbitux) to chemotherapy enabled previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis.
The combination of cetuximab and chemotherapy extended median overall survival for this population of patients by 10 months compared with chemotherapy alone.
Quote for attribution to Neal Meropol, MD, American Society of Clinical Oncology Cancer Communications Committee member ...
Month of birth impacts on immune system development
2013-04-09
Newborn babies' immune system development and levels of vitamin D have been found to vary according to their month of birth, according to new research.
The research, from scientists at Queen Mary, University of London and the University of Oxford, provides a potential biological basis as to why an individual's risk of developing the neurological condition multiple sclerosis (MS) is influenced by their month of birth. It also supports the need for further research into the potential benefits of vitamin D supplementation during pregnancy.
Around 100,000 people in the ...
Study finds key to calling back-up help when tumor-fighter p53 goes down
2013-04-09
WASHINGTON, D.C. – Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.
In a presentation at the AACR Annual Meeting 2013, scientists from The University of Texas MD Anderson Cancer Center demonstrate that tumor suppression can be restored in mice that lack p53 by knocking out the ∆N isoforms of p63 and p73 that interfere with tumor ...
AACR news: XL-184 (Cabozantinib) goes 12-for-12 in colorectal cancer explants
2013-04-09
The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. The results of this preclinical work are presented at the AACR Annual Meeting 2013.
"With molecularly targeted agents, we typically see 3 or 4 CRC explant models with a significant decrease in tumor growth. Here we have a drug that was active in every explant we tested. It's really exciting," says John Arcaroli, PhD, investigator at the University ...
AACR news: Autophagy-addicted breast cancers killed by anti-malaria drug, chloroquine
2013-04-09
The process of autophagy cleans cells – they wrap up the bad stuff and then dispose of it. And so it stands to reason that inhibiting autophagy would make cancer cells less able to cleanse themselves of chemotherapy and so more susceptible to the drugs. That's what the traditional anti-malaria drug, chloroquine, does – it inhibits autophagy. Existing clinical trials are testing chloroquine/chemotherapy combinations against breast cancer.
Research presented at the AACR Annual Meeting 2013 shows that some breast cancer subtypes depend on autophagy more than others – and ...
Possible predictive biomarker for patients who may respond to autophagy inhibitors
2013-04-09
WASHINGTON, DC – Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation. Using drugs to shut down that survival mechanism shows great promise, especially when combined with targeted agents and standard chemotherapies, but until recently, it has been unclear which patients' cancers would respond to that combination therapy.
A team led by researchers from the ...
Surface diffusion plays a key role in defining the shapes of catalytic nanoparticles
2013-04-09
Controlling the shapes of nanometer-sized catalytic and electrocatalytic particles made from noble metals such as platinum and palladium may be more complicated than previously thought.
Using systematic experiments, researchers have investigated how surface diffusion – a process in which atoms move from one site to another on nanoscale surfaces – affects the final shape of the particles. The issue is important for a wide range of applications that use specific shapes to optimize the activity and selectivity of nanoparticles, including catalytic converters, fuel cell ...
Thinking you're old and frail
2013-04-09
Older adults who categorise themselves as old and frail encourage attitudinal and behavioural confirmation of that identity.
This is the conclusion of a study conducted by Krystal Warmoth and colleagues at University of Exeter Medical School, which is being presented today, 9th April 2013, at the British Psychological Society Annual Conference in Harrogate, UK.
Krystal Warmoth interviewed 29 older adults in the South West of England face-to-face. Interviews conducted asked about their experiences of ageing and frailty. Self-perception and identification related to ...
Particles changing angle: Unexpected orientation in capillaries
2013-04-09
When small particles flow through thin capillaries, they display an unusual orientation behaviour. This has recently been discovered by a research team led by Prof. Stephan Förster and Prof. Walter Zimmermann (University of Bayreuth, Germany) at the X-ray sources DORIS III and PETRA III of the research centre DESY in Hamburg, Germany. The discovery is of major importance for spinning processes designed for the production of synthetic fibres, and for the understanding of vascular stenosis. The scientists of Bayreuth University, the Radboud University Nijmegen (Netherlands), ...
Moving cells with light holds medical promise
2013-04-09
Scientists at Washington University School of Medicine in St. Louis have shown they can coax cells to move toward a beam of light. The feat is a first step toward manipulating cells to control insulin secretion or heart rate using light.
Their research is published April 8 in the Proceedings of the National Academy of Sciences Online Early Edition.
"We have succeeded in using light as a kind of on-off switch to control cells' behavior," says principal investigator N. Gautam, PhD, a professor of anesthesiology. "Much of the way cells behave is due to their ability to ...